Overview

ZD6474 in Treating Patients With Small Cell Lung Cancer

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying how well ZD6474 works compared to placebo in treating patients with small cell lung cancer that has responded to previous chemotherapy with or without radiation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company